Co-Diagnostics, Inc. to Present at NewsMakers Conference 2017
September 07 2017 - 7:30AM
Business Wire
Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or
the “Company”), a molecular diagnostics company with a unique,
proprietary platform for the development of diagnostic tests,
announced today that CEO Dwight Egan will represent Co-Diagnostics
as a Presenting Company at the 24th Annual Biocentury NewsMakers in
the Biotech Industry conference, held on September 8 in New York
City.
According to their website, NewsMakers presents a
hand-picked group of public biotech companies whose corporate and
regulatory milestones are expected to drive stock prices, and
describes itself as the best opportunity for business development
executives and key members of the institutional investment and
analyst communities to compare notes and assess the industry
landscape. The 2016 conference represented more than 500 delegates,
including money managers with more than $600 billion in equity
assets. Co-Diagnostics will be participating as a Presenting
Company and will additionally host a table at the working luncheon.
The Company’s presentation will be available via webcast, which can
be reached here:
http://www.wsw.com/webcast/biocentury4/codg.
Mr. Egan commented: “NewsMakers is recognized as a key
venue in the industry for companies to present their story to the
investment community on Wall Street. As a NASDAQ-listed company, we
look forward to the opportunity to share our high-margin value
proposition as a dynamic company with groundbreaking technology,
and our strategy for success.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company that has developed and intends to manufacture
and sell reagents used for diagnostic tests that function via the
detection and/or analysis of nucleic acid molecules (DNA or RNA),
and to sell diagnostic equipment from other manufacturers as
self-contained lab systems.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Readers of this press release
are cautioned not to place undue reliance on any forward-looking
statements. The Company does not undertake any obligation to update
any forward-looking statement relating to matters discussed in this
press release, except as may be required by applicable securities
laws.
Disclaimer:
This news release does not constitute an offer to sell or a
solicitation of an offer to buy the securities described herein,
nor shall there be any sale of these securities in any state or
jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170907005619/en/
Co-DiagnosticsAndrew Benson, Investor
Relations801-438-1036investors@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Sep 2023 to Sep 2024